Associate Director, Clinical Pharmacology
Pfizer
Karey Kowalski, PharmD is currently an Associate Director of Clinical Pharmacology within the late stage oncology group at Pfizer focused on immuno-oncology products and is based in San Diego, CA. Karey received her Bachelor of Arts degree from the University of San Diego and her Doctor of Pharmacy degree at the University of Southern California. Karey strives to develop creative clinical pharmacology strategies to mitigate risks across the portfolio and her interests include pediatric drug development, novel application of PBPK modeling, and characterization of immunogenicity relationships with PK, safety and efficacy endpoints.
Before joining Pfizer, Karey held various roles at Ardea Biosciences (acquired by AstraZeneca in 2012) primarily working on lesinurad which was approved for gout, followed by Ignyta (acquired by Roche in 2019), primarily focused on entrectinib which was a breakthrough therapy with a novel rare disease target later approved with a pan-tumor indication (TRK) and ROS1 NSCLC.
Disclosure information not submitted.
Monday, January 10, 2022
3:15 PM – 4:15 PM ET
.png)